Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.

Although home-based working is utilized as much as possible, activities such as source data verification can only be performed onsite.

RPL is now welcoming CRA visits to recommence by adhering to the following exposure prevention policy that is designed to best mitigate risks posed by COVID-19.

View Guidelines

Latest news

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Events

HFA 2025

17–20 May 2025
Richmond Pharmacology will participate in HFA 2025 in Belgrade from 17–20 May, focusing on heart failure research, clinical trials, and scientific collaboration.
View event